Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
Adaptive Biotechnologies (Nasdaq: ADPT) will announce its financial results for Q2 2020 on August 10, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will announce its financial results for Q2 2020 on August 10, 2020, after market close. The company's conference call will start at 1:30 p.m. PT (4:30 p.m. ET). Adaptive aims to leverage the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. They have two commercial products and a robust clinical pipeline to drive future growth.
Positive
- Adaptive has two commercial products.
- Robust clinical pipeline targeting diseases like cancer and autoimmunity.
Negative
- None.
Details
News Market Reaction – ADPT
The recorded move for ADPT in the trading session of this news was -0.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter ended June 30, 2020 after market close on Monday, August 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.
Investor Contact:
Karina Calzadilla, Vice President, Investor Relations
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com
Media Contact:
Beth Keshishian
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.